96 related articles for article (PubMed ID: 3311212)
1. Increased cytotoxicity and CD16 (Leu 11) expression in long-term, IL-2-activated human peripheral blood mononuclear cells.
Podack ER; Penichet KO; Lin BY; Chiao JW; Mittelman A
Blood Cells; 1987; 13(1-2):117-22. PubMed ID: 3311212
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
4. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
6. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
7. Generation of lymphokine-activated killer cell activity from human thymocytes.
Ramsdell FJ; Golub SH
J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246
[TBL] [Abstract][Full Text] [Related]
8. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2.
Ellis TM; Creekmore SP; McMannis JD; Braun DP; Harris JA; Fisher RI
Cancer Res; 1988 Nov; 48(22):6597-602. PubMed ID: 2902918
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
Patel SS; Thiele DL; Lipsky PE
J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
[TBL] [Abstract][Full Text] [Related]
10. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
Lanier LL; Le AM; Civin CI; Loken MR; Phillips JH
J Immunol; 1986 Jun; 136(12):4480-6. PubMed ID: 3086432
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
12. Bacterial activation of human natural killer cells. Characteristics of the activation process and identification of the effector cell.
Tarkkanen J; Saksela E; Lanier LL
J Immunol; 1986 Oct; 137(8):2428-33. PubMed ID: 3093576
[TBL] [Abstract][Full Text] [Related]
13. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
Schwarz RE; Hiserodt JC
J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
15. Induction of natural killer effectors from human thymus with recombinant IL-2.
Michon JM; Caligiuri MA; Hazanow SM; Levine H; Schlossman SF; Ritz J
J Immunol; 1988 May; 140(10):3660-7. PubMed ID: 3258886
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
18. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
19. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes.
Sawada H; Abo T; Sugawara S; Kumagai K
J Immunol; 1988 May; 140(10):3668-73. PubMed ID: 2896211
[TBL] [Abstract][Full Text] [Related]
20. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
Itoh K; Tilden AB; Kumagai K; Balch CM
J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
